ImmunityBio Stock Climbs as UAE Clears ANKTIVA for Bladder and Lung Cancer
July 30, 2026 - by Gerry Griffith
Shares of ImmunityBio, Inc. (NASDAQ: IBRX) jumped roughly 7.5% after the Emirates Drug Establishment (EDE) granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two cancer indications. The approval hands the immunotherapy its broadest regulatory clearance yet and delivers on founder Patrick Soon-Shiong’s earlier “July birthday news” tease to investors.
Key Points
- The UAE approved ANKTIVA for two uses: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), including papillary-only tumors, and metastatic non-small cell lung cancer (NSCLC) that progressed despite standard therapy.
- The authorization covers ANKTIVA 0.4 mg (intravesical) with BCG and ANKTIVA 1.2 mg (subcutaneous) with immune checkpoint inhibitors.
- The UAE becomes the fifth regulatory jurisdiction to authorize ANKTIVA, expanding the drug’s footprint to 34 countries.
- Registration runs from July 2026 through July 2031, with IBRX as Marketing Authorization Holder and Modern Pharmaceutical Company as local agent.
- Shares rose nearly 8% in overnight trading, reversing a six-day losing streak.
What the UAE Approved
The EDE cleared ANKTIVA for two distinct patient populations. First, it authorized the drug in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive NMIBC. Second, it approved ANKTIVA alongside immune checkpoint inhibitors for adults with metastatic NSCLC whose disease advanced after standard-of-care treatment. Consequently, the clearance spans both of the drug’s core indications rather than a single narrow use.Clinical data underpinned both decisions. In the bladder cancer studies, ANKTIVA helped 58% of certain patients remain disease-free for a full year. Meanwhile, lung cancer patients receiving the therapy achieved a median survival of 14.6 months, reinforcing the company’s case for checkpoint-inhibitor-refractory disease.
Why It Matters for ImmunityBio’s Global Strategy
This authorization extends a deliberate Middle East push. Earlier in 2026, ImmunityBio launched ANKTIVA in Saudi Arabia after the Saudi FDA granted accelerated approval, and the company has since signaled potential expansion into markets such as Greece and Turkey. Therefore, the UAE clearance slots neatly into a broader campaign to build commercial reach outside the United States.Soon-Shiong framed the lung cancer approval as scientific validation. According to the founder, clearing patients who failed checkpoint inhibitors supports evidence that the MHC-I receptor is lost once disease progresses on those therapies. As a result, the company positions ANKTIVA not merely as a bladder cancer product but as a foundation for combination immunotherapy across tumor types.
Building Domestic Infrastructure Alongside Global Growth
While ImmunityBio expands abroad, it continues to shore up its U.S. supply chain. Notably, the company secured an exclusive agreement with Japan BCG Laboratory for the Tokyo-172 BCG strain, giving it a potential second supply source amid chronic BCG shortages. In turn, that arrangement strengthens the domestic backbone that ANKTIVA’s bladder cancer indication depends on.
Investor Takeaway
The market responded quickly, and retail sentiment on Stocktwits improved to “neutral” from “bearish” the prior day. Still, investors should weigh the news against the stock’s recent slide, which had stretched to four consecutive weekly losses before the announcement. Ultimately, the UAE approval strengthens ANKTIVA’s international momentum, yet the durability of the rally will hinge on continued commercial uptake and forthcoming U.S. regulatory milestones, including the sBLA with a PDUFA date set for January 6, 2027.
